397 related articles for article (PubMed ID: 7981461)
21. Mechanisms of growth arrest by c-myc antisense oligonucleotides in MCF-7 breast cancer cells: implications for the antiproliferative effects of antiestrogens.
Carroll JS; Swarbrick A; Musgrove EA; Sutherland RL
Cancer Res; 2002 Jun; 62(11):3126-31. PubMed ID: 12036924
[TBL] [Abstract][Full Text] [Related]
22. Effect of antiestrogens and aromatase inhibitor on basal growth of the human breast cancer cell line MCF-7 in serum-free medium.
Jensen J; Kitlen JW; Briand P; Labrie F; Lykkesfeldt AE
J Steroid Biochem Mol Biol; 2003 Mar; 84(4):469-78. PubMed ID: 12732292
[TBL] [Abstract][Full Text] [Related]
23. Effect of steroidal and nonsteroidal antiestrogens on the growth of a tamoxifen-stimulated human endometrial carcinoma (EnCa101) in athymic mice.
Gottardis MM; Ricchio ME; Satyaswaroop PG; Jordan VC
Cancer Res; 1990 Jun; 50(11):3189-92. PubMed ID: 2334915
[TBL] [Abstract][Full Text] [Related]
24. Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer.
Osborne CK; Coronado-Heinsohn EB; Hilsenbeck SG; McCue BL; Wakeling AE; McClelland RA; Manning DL; Nicholson RI
J Natl Cancer Inst; 1995 May; 87(10):746-50. PubMed ID: 7563152
[TBL] [Abstract][Full Text] [Related]
25. Antiestrogenic properties of keoxifene, trans-4-hydroxytamoxifen, and ICI 164384, a new steroidal antiestrogen, in ZR-75-1 human breast cancer cells.
Poulin R; Merand Y; Poirier D; Levesque C; Dufour JM; Labrie F
Breast Cancer Res Treat; 1989 Oct; 14(1):65-76. PubMed ID: 2605344
[TBL] [Abstract][Full Text] [Related]
26. Models of estrogen receptor regulation by estrogens and antiestrogens in breast cancer cell lines.
Pink JJ; Jordan VC
Cancer Res; 1996 May; 56(10):2321-30. PubMed ID: 8625307
[TBL] [Abstract][Full Text] [Related]
27. Anterior gradient-2 plays a critical role in breast cancer cell growth and survival by modulating cyclin D1, estrogen receptor-alpha and survivin.
Vanderlaag KE; Hudak S; Bald L; Fayadat-Dilman L; Sathe M; Grein J; Janatpour MJ
Breast Cancer Res; 2010; 12(3):R32. PubMed ID: 20525379
[TBL] [Abstract][Full Text] [Related]
28. Insulin-like growth factor binding protein 2 is a marker for antiestrogen resistant human breast cancer cell lines but is not a major growth regulator.
Juncker-Jensen A; Lykkesfeldt AE; Worm J; Ralfkiaer U; Espelund U; Jepsen JS
Growth Horm IGF Res; 2006 Aug; 16(4):224-39. PubMed ID: 16893667
[TBL] [Abstract][Full Text] [Related]
29. Cyclin D1 is necessary for tamoxifen-induced cell cycle progression in human breast cancer cells.
Kilker RL; Planas-Silva MD
Cancer Res; 2006 Dec; 66(23):11478-84. PubMed ID: 17145896
[TBL] [Abstract][Full Text] [Related]
30. Constitutive overexpression of cyclin D1 but not cyclin E confers acute resistance to antiestrogens in T-47D breast cancer cells.
Hui R; Finney GL; Carroll JS; Lee CS; Musgrove EA; Sutherland RL
Cancer Res; 2002 Dec; 62(23):6916-23. PubMed ID: 12460907
[TBL] [Abstract][Full Text] [Related]
31. MCF7/LCC9: an antiestrogen-resistant MCF-7 variant in which acquired resistance to the steroidal antiestrogen ICI 182,780 confers an early cross-resistance to the nonsteroidal antiestrogen tamoxifen.
Brünner N; Boysen B; Jirus S; Skaar TC; Holst-Hansen C; Lippman J; Frandsen T; Spang-Thomsen M; Fuqua SA; Clarke R
Cancer Res; 1997 Aug; 57(16):3486-93. PubMed ID: 9270017
[TBL] [Abstract][Full Text] [Related]
32. ICI 164,384, a pure antagonist of estrogen-stimulated MCF-7 cell proliferation and invasiveness.
Thompson EW; Katz D; Shima TB; Wakeling AE; Lippman ME; Dickson RB
Cancer Res; 1989 Dec; 49(24 Pt 1):6929-34. PubMed ID: 2582435
[TBL] [Abstract][Full Text] [Related]
33. Inhibition of tamoxifen-stimulated growth of an MCF-7 tumor variant in athymic mice by novel steroidal antiestrogens.
Gottardis MM; Jiang SY; Jeng MH; Jordan VC
Cancer Res; 1989 Aug; 49(15):4090-3. PubMed ID: 2743303
[TBL] [Abstract][Full Text] [Related]
34. Cyclin D1 expression is dependent on estrogen receptor function in tamoxifen-resistant breast cancer cells.
Kilker RL; Hartl MW; Rutherford TM; Planas-Silva MD
J Steroid Biochem Mol Biol; 2004 Sep; 92(1-2):63-71. PubMed ID: 15544931
[TBL] [Abstract][Full Text] [Related]
35. Differential effects of estradiol and its analogs on cyclin D1 and CDK4 expression in estrogen receptor positive MCF-7 and estrogen receptor-transfected MCF-10AEwt5 cells.
Hong J; Shah NN; Thomas TJ; Gallo MA; Yurkow EJ; Thomas T
Oncol Rep; 1998; 5(5):1025-33. PubMed ID: 9683804
[TBL] [Abstract][Full Text] [Related]
36. Induction of estrogen independence of ZR-75-1 human breast cancer cells by epigenetic alterations.
van Agthoven T; van Agthoven TL; Dekker A; Foekens JA; Dorssers LC
Mol Endocrinol; 1994 Nov; 8(11):1474-83. PubMed ID: 7533260
[TBL] [Abstract][Full Text] [Related]
37. Human estrogen receptor ligand activity inversion mutants: receptors that interpret antiestrogens as estrogens and estrogens as antiestrogens and discriminate among different antiestrogens.
Montano MM; Ekena K; Krueger KD; Keller AL; Katzenellenbogen BS
Mol Endocrinol; 1996 Mar; 10(3):230-42. PubMed ID: 8833652
[TBL] [Abstract][Full Text] [Related]
38. Lycopene inhibition of IGF-induced cancer cell growth depends on the level of cyclin D1.
Nahum A; Zeller L; Danilenko M; Prall OW; Watts CK; Sutherland RL; Levy J; Sharoni Y
Eur J Nutr; 2006 Aug; 45(5):275-82. PubMed ID: 16565789
[TBL] [Abstract][Full Text] [Related]
39. Synthetic antiestrogens modulate induction of pS2 and cathepsin-D messenger ribonucleic acid by growth factors and adenosine 3',5'-monophosphate in MCF7 cells.
Chalbos D; Philips A; Galtier F; Rochefort H
Endocrinology; 1993 Aug; 133(2):571-6. PubMed ID: 8344199
[TBL] [Abstract][Full Text] [Related]
40. Additive growth inhibitory effects of ibandronate and antiestrogens in estrogen receptor-positive breast cancer cell lines.
Journe F; Chaboteaux C; Magne N; Duvillier H; Laurent G; Body JJ
Breast Cancer Res; 2006; 8(1):R2. PubMed ID: 16417650
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
